On the stock market since 2017, it operates in the world of health and science. It has 35 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 208% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades below its recent peak — about 11% off the top. A pullback, not a collapse.
Sales run at $44.6M a year. A small number, but proof the product has real buyers.
There is $36.7M in the vault; even if every debt were paid off, $36.7M would remain.
The average analyst price target is $16.00 — 54% above today’s price.
A loss of $9.7M against $44.6M in annual sales. And on top of that, sales fell from the year before.
The growth engine is running at low revs right now. Report-card grade: 27/100.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 43/100.
On our five-subject report card, FENC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: FENC is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (53/100) says the stock isn’t cheap.